Literature DB >> 9779382

Intrapulmonary concentrations of antimicrobial agents.

D E Nix1.   

Abstract

The delivery of antimicrobial agents to the site of infection has always been considered important. Lung infections are typically localized to the bronchial mucosa, endothelial lining fluid, and/or alveolar macrophages. Significant advances have been made in measuring antimicrobial concentrations at these sites, although some of the methods need further refinement and standardization. Relating various intrapulmonary site concentrations to efficacy or treatment failure requires further study. This article reviews the theory and methods relating to the measurement of intrapulmonary delivery of antimicrobial agents, and compares the intrapulmonary delivery of agents commonly used for the treatment of lower respiratory infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779382     DOI: 10.1016/s0891-5520(05)70202-6

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  12 in total

1.  Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Authors:  Ana Motos; Joseph L Kuti; Gianluigi Li Bassi; Antoni Torres; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

3.  Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.

Authors:  David Tenero; Gary Bowers; Keith A Rodvold; Apurva Patel; Milena Kurtinecz; Etienne Dumont; John Tomayko; Parul Patel
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

4.  Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.

Authors:  Blair Capitano; Brian A Potoski; Shahid Husain; Shimin Zhang; David L Paterson; Sean M Studer; Kenneth R McCurry; Raman Venkataramanan
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Anasuya Patel; Rajesh Chavan; Ravindra Yeole; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Ravindra Yeole; Anasuya Patel; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

8.  Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Authors:  Andreas H Groll; Caron A Lyman; Vidmantas Petraitis; Ruta Petraitiene; Derek Armstrong; Diana Mickiene; Raul M Alfaro; Robert L Schaufele; Tin Sein; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of quinupristin/dalfopristin.

Authors:  David T Bearden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors:  Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.